The animal study results demonstrate that ATH434 can reduce the motor symptoms of both MSA and PS and we are expecting that the same would happen in humans. Possibly, the open study in the MSA population can demonstrate it. As you notice (NEJM and Nature report this) this would be big news as is this Lixisenatide even it does not improve the symptoms but only stops the progression.
Stamler knows what will happen in the symptom scores of the open study during the first 6 months. Will he report it, is still unknown as is if ATH434 reduces the blood alpha-synuclein. Claassen also knows these scores but will he only report the neurofilament light gets higher when the symptoms get worse and not to tell anything about the open study results?
The animal study results demonstrate that ATH434 can reduce the...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $501.4K | 91.10M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 71 | 70438990 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 7499794 | 14 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
-0.001 ( 8.33 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 3568393 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| ATH (ASX) Chart |